Weekly roundup: Another busy week in biopharma

/in

Cycuria Therapeutics launched with a distinguished advisory board and significant public grant funding Cycuria Therapeutics launched, announcing a distinguished Advisory Board and the successful approval of grant funding from two leading Austrian national funding organisations. Cycuria is developing a first-in-class, protein-based therapy with a differentiated dual-mechanism for hard-to-treat blood cancers, including acute myeloid leukaemia (AML). Novo […]

Read more

Hot topic: Pandemics and the price of eggs

/in

Here in Britain, as elsewhere in Europe, we are used to the price of eggs having risen since the Covid pandemic. It’s okay though, prices have stabilised and have even come down slightly.  But in the US the high price of eggs – taken as emblematic of the country’s dissatisfaction with the Biden administration as […]

Read more

Weekly round-up: A fund aiming to free a whopping $30bn of trapped biotech capital, strategic hires, plus a new episode of ‘Dealmakers’ on Optimum TV

/in

Renée Aguiar-Lucander appointed Chief Executive Officer of Hansa Biopharma   Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics AB where she successfully led the company through a dual listing on NASDAQ in both Sweden […]

Read more

Hot topic: What does the future hold for vaccines?

/in

Vaccines are not a new medical technology. It is almost 230 years since Edward Jenner, a British doctor, inoculated eight-year-old James Phipps with fluid from a cowpox sore in a successful attempt to prove it would protect the boy from the scourge of the time, smallpox. So, it is perhaps surprising that scepticism and downright […]

Read more

Will Trump hit foreign pharma companies with tariffs?

/in

Well, the last fortnight’s certainly been a rollercoaster. Ever since President Trump announced his plans for sweeping tariffs on foreign goods entering the US on Thursday April 3, markets have hardly been able to catch their collective breath. First there was the initial shock, at which point stocks tanked, before lurching up and down, and […]

Read more
© Optimum Strategic Communications.